Antimicrobial Emulsifier-Glycerol Monolaurate Induces Metabolic Syndrome, Gut Microbiota Dysbiosis, and Systemic Low-Grade Inflammation in Low-Fat Diet Fed Mice
Antimicrobial Emulsifier-Glycerol Monolaurate Induces Metabolic Syndrome, Gut Microbiota Dysbiosis, and Systemic Low-Grade Inflammation in Low-Fat Diet Fed Mice
复制标题
DOI:
10.1002/mnfr.201700547
复制
发表时间:
2018-02-01
影响因子:
5.2
通讯作者:
Feng,Fengqin
中科院分区:
文献类型:
--
作者:
Jiang,Zengliang;Zhao,Minjie;Feng,Fengqin
ScopeGlycerol monolaurate (GML) is widely consumed worldwide in the food industry and is considered safe, but for chronic diseases, supporting scientific data remain sparse. This study investigates whether dietary GML induces metabolic syndrome, gut microbiota dysbiosis, and systemic low‐grade inflammation.Methods and resultsGML‐induced occurrence of metabolic syndrome, gut microbiota alterations, and systemic low‐grade inflammation are investigated. The results demonstrate that GML induced metabolic syndrome by significantly increasing the body weight, weight gain, food intake, body fat, fat droplet size and percentage of epididymal fat, serum triglycerides (TG), LDL, and atherogenic index, and decreasing the body muscle ratio, liver weight, and HDL, compared to the control (CON) group. Meanwhile, GML significantly changed the β‐diversity and composition of gut microbiota and upregulated the circulating levels of serum LPS, IL‐1β, IL‐6, and TNF‐α. Importantly, GML significantly decreasedAkkermansia muciniphilaandLupinus luteus, and increasedBacteroides acidifaciens,Escherichia coliand the microbial DNA abundance of the ten predicated metabolism pathways involved in carbohydrate, amino acid, and lipid metabolism.ConclusionOur results indicate that relatively low‐dose GML consumption promotes metabolic syndrome, gut microbiota dysbiosis, and systemic low‐grade inflammation, thereby calling for a reassessment of GML usage.